Ceva Sante Animale

Flamel Technologies

Flamel Ireland Limited

Smithkline Beecham Corporation

Florence Guimberteau

Catherine Castan

Rémi Meyrueix

Anne-Claire Le Meur

Sandrine Lacoste

Frederic Dargelas

Gerard Soula

Remi Meyrueix

Gérard Soula

Hamadi Karembe

Laurence Peyrot

Edouard Timsit

Rémi Soula

Jérôme Guyonnet

Patrick Forget

Vassilios Kaltsatos

Romain Delcombel

Rémi Meyruiex

Frédéric Dargelas

Anne Geneteau

Gautier Barthelemy

Anne-Sophie Daviaud

Anne Claire Le Meur

Evelyne Coussanes

Choon Oh

Patrick J Crowley

The present invention relates to a nose ring for ruminants such as cattle, comprising a ring body () having an extra-nasal part () and intra-nasal parts () extending on either side of this extra-nasal part (), each of these intra-nasal parts () carrying a plate () intended to bear against the nasal septum separating the nasal cavities of a ruminant, said bearing plates () thus being placed at the ends of said nose ring. According to the invention, each bearing plate has an elongate shape and comprises opposite ends, at least one of which is wider than the central region thereof placed between said two ends, each plate being convex and having a front face intended to come into contact with the nasal wall of the animal, the surface area of which front face is at least equal to 500 mmand preferably at least equal to 1500 mm, and even more preferably at least equal to 2000 mm, each bearing plate thus being capable of maximising the contact surface with the nasal septum for different nasal morphologies in order to ensure that this ring is retained without injuring the animal.

Nose ring for ruminants

The present invention relates to a veterinary composition comprising an iron complex as a sole active ingredient and a water-soluble polymer. The invention further relates to the use of such composition for controlling iron deficiencies and/or anaemic states in a non-human mammal.

Veterinary compositions and the uses thereof for controlling iron deficiencies in non-human mammals

Nose ring for animals

The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Triazine formulations with a second active ingredient and surfactant(s)

The present invention relates to a veterinary or pharmaceutical composition comprising: (i) about 1-65% w/v of a pyrethroid, or a salt thereof, (ii) a macrocyclic lactone, or a salt thereof, (iii) at least one alkalizing agent, (iv) at least one non aqueous solvent, wherein the pH of the composition is comprised between about 6.5 and 8.5, when measured by adding 25% of water to an aliquot of said composition. The invention further relates to the use of such composition for preventing and/or treating parasites infestations.

Composition for treating parasites infestations

The present invention relates to an injectable implant comprising an effective amount of a macrocyclic lactone, or a salt thereof, and a bioresorbable polymer, and its use in preventing and/or treating parasites infestations in non human mammals, especially pets.

Solid injectable veterinary implants comprising monocyclic lactone

The present invention is directed to palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing oral veterinary compositions. Various aspects of the present invention are related to preparing palatable veterinary compositions that comprises mixing one or more pharmaceutical active ingredients having a smell with one or more palatabilizing agents.

Palatable oral veterinary compositions

The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.

The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: 'time triggering' and 'pH triggering'. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.

Oral medicinal product with modified release of at least one active principle in multimicrocapsular form

The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).

Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)

Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.

Prolonged-release multimicroparticulate oral pharmaceutical form

Growing community of inventors

Montussan, France

Florence Guimberteau